Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-Squamous Non Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II/III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Erlotinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms TASTE
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.